



## Current Molecular Research on Skin Diseases

Guest Editors:

**Dr. Luca Potestio**

**Prof. Dr. Gabriella Fabbrocini**

**Dr. Matteo Megna**

**Dr. Angelo Ruggiero**

Deadline for manuscript  
submissions:

**closed (30 June 2024)**

### Message from the Guest Editors

COVID-19 revolutionized daily clinical practice. In particular, several strategies were adopted to avoid the spreading of the infection as well as the epidemiology, and the management of several dermatological conditions completely changed, for example, psoriasis, atopic dermatitis, hidradenitis suppurativa, and skin cancers. Several skin manifestations were related to COVID-19 itself, as well as the safety of many dermatological treatments, such as biological drugs, was questioned during the pandemic. Among the measures adopted to avoid the propagation of the infection, telemedicine was crucial to allowing therapeutic assistance without increasing the risk of the infection. Similarly, the introduction of the COVID-19 vaccination had the greatest impact on overcoming the pandemic.

This Special Issue is now open for submissions, welcoming papers that bring together the most relevant scientific research investigating how COVID-19 impacted the management of skin diseases, focusing on epidemiology and treatment, as well as the role of teledermatology in the pandemic period and of the dermatologist during the vaccination campaign.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI